Novel Anthrax Vaccine

Last Editorial Review: 9/2/2003

Remember the anthrax scare? Even though anthrax is not currently Front Page News, scientists are busy developing new anthrax vaccines. One such vaccine being tested in mice sounds promising. It is a dual-action vaccine that simultaneously protects both against the anthrax bacteria and the deadly toxins released by the bacteria. This is important because the anthrax vaccine currently in use only targets the toxins.

Comment: If this vaccine is successfully tested in humans, it might help dispel the specter of a future anthrax attack.

For additional information, please visit the following areas:

  • Anthrax (main article)
  • Anthrax, From Russia with Love
  • Anthrax, Then and Now
  • Anthrax Center
  • Bioterrorism Center

Barbara K. Hecht, Ph.D.
Frederick Hecht, M.D.
Medical Editors,

Mouse study gives new view of anthrax toxin

Sept. 2, 2003 -- A large-scale study of anthrax in mice has yielded new information about immune system response to anthrax bacteria, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health. The discovery that toxins released by the bacteria do not behave as previously believed should redirect approaches to anthrax drug design, notes NIAID Senior Investigator Stephen Leppla, Ph.D., whose research is published in today's issue of the "Journal of Clinical Investigation".

In the new study, Dr. Leppla and his colleagues injected hundreds of inbred mice with anthrax lethal toxin (LT), and then took precisely timed measurements to determine how various organs and immune system processes responded. For example, they measured levels of chemicals called cytokines, which are released by immune system cells after a bacterial invasion. Dr. Leppla and his colleagues found no evidence of a persistent increase in cytokines, or of a link between cytokine increase and anthrax LT effects, contradicting earlier beliefs.

The evidence suggests that current efforts to design cytokine-suppressing drugs to treat lethal toxin-mediated events in late stages of anthrax may be misguided. "Finding effective therapies for diseases such as inhalational anthrax depends on our ability to connect basic research with clinicians' needs. This research is a perfect example of such translational research," says NIAID Director Anthony S. Fauci, M.D.

"Science has had a good understanding of anthrax toxins at molecular and subcellular levels," says Dr. Leppla. "What has been lacking is a picture of the much more complex effects of toxins on tissues and animal models. Ours is one of the first comprehensive studies to critically examine what is actually happening at these higher levels of complexity."

In a natural infection, inhalational anthrax begins after anthrax bacteria spores enter the body, germinate and release toxins. Scientists can create artificial infection by injecting animals with anthrax LT. The accumulation of toxins precipitates events that lead to death. For more than a decade, scientists based their understanding of LT actions on the results of a few studies that employed a limited number of mice. Because of the high cost of doing anthrax toxin research and the small number of anthrax researchers, theories about LT action went largely unquestioned.

"We still do not know how LT brings about the hypoxia and shock-like death we see in mice," says the paper's first author, Mahtab Moayeri, Ph.D. The next important step, she adds, will be to identify the cell targets of LT and determine precisely how it initiates the chain of events leading to death.

Source: National Institute of Allergy and Infectious Diseases (NIAID)


The 14 Most Common Causes of Fatigue See Slideshow

Health Solutions From Our Sponsors